Progenics Pharmaceuticals Sets 4Q and Year-End 2013 Financial Results Call for March 13

        Print
| Source: Progenics Pharmaceuticals Inc.

TARRYTOWN, N.Y., March 10, 2014 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative ways to target and treat prostate cancer, announced today that it will host a conference call and webcast to review fourth quarter and full-year 2013 financial results on Thursday, March 13, at 8:30 a.m. ET.

To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international) and reference conference ID 6290854. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a replay will be available for two weeks.

About Progenics

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes therapeutic and diagnostic candidates in late-stage clinical development. Progenics recently completed enrollment of the original cohort of chemotherapy experienced patients in a Phase 2 trial of PSMA ADC, its antibody-drug conjugate therapeutic. Enrollment of a chemotherapy naive cohort is ongoing. Enrollment was also recently completed in a Phase 2 trial of Progenics diagnostic imaging agent, 1404. Azedra, a therapeutic candidate with orphan drug designation in a Phase 2 trial under a SPA, is resuming and patient enrollment is expected to continue after re-starting drug supply manufacturing. Progenics' first commercial product, Relistor® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. Please visit us at www.progenics.com.

(PGNX-F)

Kathleen Fredriksen
Corporate Development
(914) 789-2871